CTRI’s Wallace Named to Medical/Scientific Board

Mark Wallace

CTRI Clinical Research Director Mark Wallace

An article about CTRI Clinical Research Director Mark Wallace, "Inergetics Appoints Mark Wallace, MD as Member of Medical/Scientific Advisory Board for Development of CBD-Based Nutritional Supplements," was published in the March 26 edition of the Wall Street Journal. Dr. Wallace's role on the board will be to "guide the formulation of a proprietary line of natural cannabidiol (CBD)-based nutritional supplements" the company is developing with Terra Tech Corp, according to the news announcement. Dr. Wallace, an anesthesiologist, is an expert in pain management.

 

 






About UC San Diego Altman Clinical and Translational Research Institute:

UC San Diego Altman Clinical and Translational Research Institute (ACTRI) is part of a national Clinical and Translational Science Award consortium, led by the National Institutes of Health National Center for Advancing Translational Science. Established in 2010, ACTRI provides infrastructure and support for basic, translational and clinical research throughout the San Diego region to bring discoveries from the laboratory to the bedside, and facilitates training and education of the next generation of researchers. ACTRI carries out its activities in collaboration with institutional and corporate partners and currently has more than 1,500 members.

actri.ucsd.edu